Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 137 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR New independent tobacco review sets roadmap for a smokefree England for... June 9, 2022 10 Things I Wish I Knew When I Was First Diagnosed... July 19, 2022 Mom Warns Others After Little Girl’s Skin Blisters From ‘Margarita Burn’ July 31, 2019 Today is Veterans Day November 11, 2020 Load more HOT NEWS Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients... EMA Recommends to Extend the Indications for Tislelizumab EMA Recommends Granting a Marketing Authorisation for Mirvetuximab Soravtansine Adding Blinatumomab to Consolidation Chemotherapy Improves OS in Adult Patients in...
